After nearly two decades of work in three multinational pharmaceutical companies – French, German, and American – Carlos Jorge Monteiro decided to found Biojam, SA, initially with a partner who later pursued a different path. Subsequently, in 2015, the entrepreneur established the Biojam Holding Group.
In a timely interview with PAÍS€CONÓMICO, Carlos Monteiro, CEO of Biojam Holding Group, discussed the work carried out by Biojam during these challenging pandemic times, where it stood out primarily in the areas of antigen testing and the launch of a range of oral hygiene products specially dedicated to people with diabetes.
"Innovation is in Biojam's DNA, and we work every day to develop new products or solutions, and that, for us, is innovation, as happened in the paradigmatic case of the new solutions we implemented for Acute Lymphoblastic Leukemia, primarily targeted at children and young people."
The success has been so impactful that Biojam is set to enter new international markets, such as Mexico, Colombia, and Chile in Latin America, as well as the Benelux countries – Belgium, the Netherlands, and Luxembourg. The entrepreneur believes that Portugal can play an important role in the international pharmaceutical industry, "as we know how to do it so well, with quality and competitiveness, like any other nation," emphasizes Carlos Monteiro, who also points to a very substantial increase in Biojam's turnover in 2022.
You can read the full interview in País Económico magazine.
